Attorney Docket No.: 10377.204-US

JC17 Rec'd PCT/PTO 20T9 WN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu et al.

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: June 20, 2005

Examiner: To be assigned

For: Polypeptides Having Cellobiohydrolase II Activity and Polynucleotides Encoding Same

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: June 20, 2005

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

New York, NY 1011 (212) 840-0097

JC17 Recti 27/PTO 2,0 JUN 2005

10377.204-US

Approved through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Ones: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Application Number

Filing Date

First Named Inventor

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

Sheet

1

of

2

		U.	S PATENT DOCU	MENTS	
Examiner Initials	Cite No. 1	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 6,114,158	09-05-2000	Li et al	
					· · · · · · · · · · · · · · · · · · ·
				, , , , , , , , , , , , , , , , , , ,	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т 6
		EP 851 031	07-01-1998	Rohm Enzyme Finland Oy		
		WO 85/04672	10-24-1985	Valtion Teknillinen Tutkimuskeskus		
		WO 91/17244	11-14-1991	Novo Nordisk A/S		
		·				
	<u> </u>					_
	-					
	<u> </u>					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

JC17 Rec'd FUT/PTO 20 JUN 2005

PTO/SB/08A (10-01)

through 10/31/2002. OMB 0651-0031

Approved U.S. Patent and Trademark Onnee. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control remove 1440A/PTO

Complete if Known 1449A/PTO **Application Number** To be assigned INFORMATION DISCLOSURE Filing Date June 20, 2005 STATEMENT BY APPLICANT First Named Inventor Wu et al. (use as many sheets as necessary) Art Unit To be assigned **Examiner Name** To be assigned Sheet 2 of 2 **Attorney Docket Number** 10377.204-US

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
		TUULA T. TEERI ET AL., Gene, Vol. 51, pages 43-52 (1987)				
	 					
	ļ					
	;					
	<u> </u>					
	[

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.